RLMD Share Price Performance
US$0
-0.27 (-100.00%)
Price US$0
Fair ValueUS$10.75
Share Pricen/a
Relmada Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
RLMD Community Narratives
AN
Fair Value US$10.75 35.3% undervalued intrinsic discount
Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$19 63.4% undervalued intrinsic discount
Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsivity related neurological disorders. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$19
63.4% undervalued intrinsic discount
Fair Value
Profit Margin
20.06%
Future PE
249.93x
Price in 2029
US$0
Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsive behavior disorders such as Prader Willi syndrome. What are the underlying business or industry changes driving this perspective?Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$10.75
35.3% undervalued intrinsic discount
Fair Value
Profit Margin
21.47%
Future PE
4.01kx
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech
Fair Value: US$19 63.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook
Fair Value: US$10.75 35.3% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Relmada Therapeutics, Inc. Key Details
About RLMD
- Founded
- 2004
- Employees
- 17
- CEO
- WebsiteView website
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
